Strategic potential of the CD38 target and anti-CD38 nano-antibodies developed by NVDIAG

Strategic potential of the CD38 target and anti-CD38 nano-antibodies developed by NVDIAG

 

In the current biotechnology development landscape, the CD38 target and anti-CD38 antibodies represent a major scientific, industrial and economic opportunity. The NVDIAG Labcom, born from a collaboration between CNRS/Aix-Marseille Université (LISM) and BioCytex (Stago Group), is developing nanobodies (VHH) targeting CD38, designed to improve the in vitro diagnosis of haematological diseases, particularly multiple myeloma. This initiative illustrates the French model of public-private valorisation and meets the expectations of technology transfer and valorisation stakeholders, as well as venture capital investors specialised in biotechnologies.

Read the full article (French version)